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Encoding the CFTR-Activating Guanylate Cyclase 2C
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Meconium ileus, intestinal obstruction in the newborn, is caused inmost cases by CFTRmutationsmodulated by yet-unidentifiedmodi-
fier genes. We now show that in two unrelated consanguineous Bedouin kindreds, an autosomal-recessive phenotype of meconium ileus
that is not associated with cystic fibrosis (CF) is caused by different homozygous mutations in GUCY2C, leading to a dramatic reduction
or fully abrogating the enzymatic activity of the encoded guanlyl cyclase 2C. GUCY2C is a transmembrane receptor whose extracellular
domain is activated by either the endogenous ligands, guanylin and related peptide uroguanylin, or by an external ligand, Escherichia coli
(E. coli) heat-stable enterotoxin STa. GUCY2C is expressed in the human intestine, and the encoded protein activates the CFTR protein
through local generation of cGMP. Thus, GUCY2C is a likely candidate modifier of the meconium ileus phenotype in CF. Because
GUCY2C heterozygous and homozygous mutant mice are resistant to E. coli STa enterotoxin-induced diarrhea, it is plausible that
GUCY2C mutations in the desert-dwelling Bedouin kindred are of selective advantage.Meconium ileus (MI), intestinal obstruction by inspissated
meconium in the distal ileum and cecum, develops in
utero and presents shortly after birth as failure to pass
meconium.1 Some 80% of MI cases are caused by cystic
fibrosis transmembrane conductance regulator (CFTR
[MIM 602421]) mutations.2,3 In fact, 15%–20% of infants
with cystic fibrosis (CF [MIM 219700]) develop MI as
a presenting symptom.1 The predisposition to MI in CF is
genetically determined;4–8 some CFTR mutations lead to
MI at a higher incidence than others.6,9–17 This predisposi-
tion is modified by yet other, unidentified genes, residing
in several genomic loci.16–22 Non-CF MI can be caused by
an array of etiologies, from defects in intestinal innerva-
tion to pancreatic insufficiency and meconium plug
syndrome, to various anorectal malformations.23
We have previously described inbred consanguineous
Bedouin kindred with autosomal-recessive MI, a normal
sweat test, and no further clinical stigmata of CF.24 Intes-
tinal biopsy done in three of the affected individuals
demonstrated normal ganglions and cholinergic neurons.
On the basis of the extended pedigree (Figure 1A, family 1),
we assumed a founder effect. Following Soroka Medical
Center institutional review board approval and informed
consent, DNA samples of 11 affected and 26 nonaffected
individuals from the kindred were obtained. Homozy-
gosity of affected individuals at the CFTR locus was ruled
out via polymorphic markers D7S2460, D7S677, and
D7S655 within CFTR as previously described25,26 (data
not shown). Genome-wide linkage analysis (ABI PRISM
Linkage Mapping Set, Applied Biosystems) was done as
previously described,25,26 and identified a single locus of1The Morris Kahn Laboratory of Human Genetics, National Institute for Biot
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The Amhomozygosity on chromosome 12p13 (spanning 9.5 Mb
between markers D12S366 and D12S310) that was
common to all affected individuals. Fine mapping of the
locus was done with polymorphic markers as previously
described26 and narrowed down the locus to 4Mb between
markers D12391 and Ch12_TG (Figure 1B). Maximal two-
point LOD score (SUPERLINK)27 was 4.1 (theta ¼ 0) at
D12S1580. Of the 40 genes within that locus, our S2G soft-
ware28,29 identified GUCY2C (MIM 601330) as the primary
candidate gene. Sequencing of the entire coding sequence
and exon-intron boundaries of GUCY2C (NM_004963.3)
identified a single homozygous mutation, c.1160A>G,
leading to p.(Asp387Gly) amino acid substitution in the
encoded protein. The mutation was not found in any
SNP or mutation database and was common to all affected
individuals (Figure 2). At the position of the c.1160A>G
mutation, BanI restriction analysis gave differential
cleavage products for the wild-type and mutant sequences
(207 bp in the wild-type versus 134 bp and 73 bp fragments
in the mutant; PCR amplification primers: forward 50-
TCCAACTTATCTGTCAGGCAAA-30; reverse 50-GTTACC
CCTCCTCACCCAGT-30). This differential BanI restriction
analysis was used to test the 37 DNA samples in family 1
as well as controls. Of the 24 nonaffected individuals in
the kindred, three offspring of a consanguineous marriage
and one obligatory carrier were homozygous for the muta-
tion. However, partial penetrance of the phenotype was
evident: one of the three that had been examined by ultra-
sonography late in pregnancy had unequivocal intra-
uterine sonographic evidence of meconium ileus, yet did
pass stools unassisted after birth. Of 240 unrelated Bedouinechnology in the Negev, Ben Gurion University, Beer-Sheva 84105, Israel;
ivision of obstetrics and gynecology, Soroka Medical Center, Beer-Sheva
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Figure 1. Family Trees and Linkage Analysis Results
(A) The Israeli-Bedouin Kindred affected with non-CF MI; family 1 and family 2 are not related.
(B) Linkage analysis results (chromosome 12p13, partial pedigree of family 1): the haplotype showing the homozygosity region is boxed.
Physical locations of the markers are shown. Individuals VII:8, VII:9 defined the upper boundary of the locus and individual VII:23
defined the lower boundary. For tested individuals, the c.1160A>G mutation status of each allele is marked as wild-type (WT) or
mutant (M).controls, three3 were found to be heterozygous for the
mutation and none were homozygous. The penetrance of
the postnatal MI phenotype in c.1160A>G homozygous
individuals was 73% (11 affected/15 mutants).
GUCY2C encodes guanylyl cyclase 2C, a regulator of
ion and fluid balance in the intestine and harbors an
N-terminal extracellular ligand-binding domain, a single
transmembrane domain, and a C-terminal intracytoplas-894 The American Journal of Human Genetics 90, 893–899, May 4, 2matic guanylyl cyclase domain.30,31 The extracellular
domain of GUCY2C is targeted by either the endogenous
ligands, guanylin and related peptide uroguanylin, or
by an external ligand, E. coli heat-stable enterotoxin
STa.30,32–35 Binding of the physiological ligands or of STa
to the extracellular domain of GUCY2C activates the intra-
cellular cyclase domain, which catalyzes the synthesis of
the second messenger cyclic GMP (cGMP) from GTP.31–35012
Figure 2. The c.1160A>G and
c.2270dupA GUCY2CMutations: Homozy-
gosity for the Wild-Type Allele
(A–F) Heterozygosity for the wild-type
(A and D) and the mutated alleles (B and
E) and homozygosity for themutated allele
(C and F) in normal obligatory carriers and
affected individuals of families 1 (A, B, and
C) and 2 (D, E, and F). (G) The p.Asp387Gly
amino acid substitution: multiple align-
ment and conservation analysis (ClustalW)
of humanGUCY2Cwith its orthologs. (the
asterisk [*] represents the mutated amino
acid).
(H) The p.Asn757Lysfs*2 mutation:
deleting the functional domain of the
enzyme (SMART).Elevated levels of cGMP in response to ligand binding
cross-activate cGMP-dependent protein kinase G II
(PKGII); this activation leads to phosphorylation and
subsequent opening of the CFTR.31 This signaling cascade
leads to chloride and bicarbonate secretion, ultimately
driving the paracellular movement of sodium into the
intestinal lumen and regulating intestinal ion and water
transport.31The American Journal of HumaGUCY2C is predominantly local-
ized at the apical brush border mem-
brane of the intestinal epithelium:
specific STa-binding sites are present
in apical membranes of intestinal epi-
thelium from the duodenum to the
distal colon.36,37 The highest density
of GUCY2C receptor molecules is
found in the proximal small intestine
and decreases progressively distally.36
The endogenous peptides guanylin
and uroguanylin have a lower affinity
for GUCY2C than do the STa peptides
and are produced within the in-
testinal mucosa to serve as paracrine
and autocrine regulators of intestinal
fluid and electrolyte secretion.38 The
toxic E. coli STa peptide is a major
pathogen in humans that causes
acute and secretory diarrhea in in-
fants, travelers, and domestic animals
and has a geographic distribution pri-
marily in developing countries:39,40
when targeted by exogenous STa,
GUCY2C is overactivated and intra-
cellular cGMP is induced, resulting
in imbalance in the secretion of fluids
and chloride from intestinal cells and
culminating in severe secretory diar-
rhea in both humans and mice.31,41–43
Protein levels of GUCY2C receptors
are highest in newborns and neonates
(in which STa-mediated diarrhea ismore frequent and more severe)44, and their affinity and
density rapidly decrease with increasing age in humans,45
as well as in mice,46 rats,47 and pigs.48
The p.(Asp387Gly) substitution (Figure 3G) found in the
affected individuals is in a conserved aspartate residue of
GUCY2C that is within one of the two essential regions of
its extracellular ligand-binding domain (Figure 3H) and is
immediately adjacent to seven other amino acids that aren Genetics 90, 893–899, May 4, 2012 895
Figure 3. Functional Analysis of the c.1160A>G Mutation that
Produces p.Asp387Gly
(A and B) Immunoblot analysis showing equal amounts of wild-
type (GCC) and mutant (GCCD387G) protein in stable transfected
HEK293 cell lines used for testing GUCY2C activity.
(C) GUCY2C activity in the presence (þSta) or absence (no Sta) of
E. coli heat-stable enterotoxin STa, tested in HEK293 cells stably
transfected with either empty pcDNA vector (negative control)
or wild-type (GCC) or mutant (GCCD387G) GUCY2C. Each experi-
ment represents mean 5 standard deviation of three repeats.
Similar results obtained for three different pairs of cell lines stably
overexpressing equal amounts of mutant and wild-type GUCY2C.cardinal to ligand binding.49 In fact, in the porcine
GUCY2C ortholog, substitution by alanine residues of
Asp387 together with two amino acid residues surrounding
it, leads to a significant reduction in ligand-binding and to
a reduction in guanylate cyclase activity.30,49
To prove experimentally the effect of the p.(Asp387Gly)
substitution on the guanylate cyclase activity of the
GUCY2C protein, we transfected HEK293 cells (which
normally do not express GUCY2C) with either the wild-
type or the mutant GUCY2C. To that end, we first cloned
the full-length wild-type 3.4 Kb human GUCY2C cDNA
into the mammalian expression vector pcDNA3 (Invitro-
gen, Life Technologies), generating a construct we termed
pcDNAhGCC. Site-directed mutagenesis was performed
on the cloned wild-type GUCY2C and generated the
mutant gene by overlapping PCR amplification: first, two
PCR products, including the mutation site, were amplified
with primers designated with the mutation site (one of the
primers of each pair). Then, we further used these two PCR
products as a template to amplify the whole fragment
flanking the mutation region by using the other primers
of each pair (primer sequences available upon request).
This fragment was subcloned into the pGEM-T easy vector
and confirmed by sequencing. The digestion of the result-
ing construct with EcoRV and BamHI yielded a fragment
that contained the mutation region and was inserted in-
frame into the corresponding sites in the pcDNAhGCC
plasmid. This insertion generated the pcDNAhGCCA1207G
clone containing the full length of the mutated GUCY2C
(GUCY2CA1207G) cDNA. The final plasmid full sequences
were verified by sequencing (data not shown). HEK293896 The American Journal of Human Genetics 90, 893–899, May 4, 2cells were then stably transfected with constructs encoding
either the wild-type or the mutant GUCY2C. Transfection
was done with TransIT-LT1 reagent (Mirus) per kit instruc-
tions, verified by immunoblot analysis as previously
described,25 and quantifiedwith a densitometer (Multigage
software, Fujifilm). FACS analysis of theHEK293:hGCCand
HEK293:hGCCD387G cell lines with the GUCY2C mono-
clonal antibody and second FITC antibody demonstrated
that both the wild-type and the mutated GUCY2C were
expressed on the plasma membrane (data not shown).
Thus, we concluded that the mutation does not prevent
expression of the ligand-stimulated form of the receptor
on the cell surface.
We proceeded to test the effect of the p.(Asp387Gly)
substitution on guanylate cyclase catalytic activity. We
selected three pairs of stable transfected cell lines that
express equivalent levels of wild-type versus mutant pro-
teins as demonstrated by immunoblot analysis (Figure 3)
and verified quantitatively. Each of the three pairs of cell
lineswas analyzed (in triplicates) for guanylate cyclase cata-
lytic activity, measuring the formation of intracellular
cGMP levels in response to extracellular STa as previously
described.34 In essence, HEK293 cells were cultured in
24-well plates. After 24hr, the culturemediumwas removed
and the cells were incubated in 500 ml serum-free medium
containing 100 mM 3-isobutylmethyl-1-xanthine (IBMX)
(Sigma) for 10 min at 37C in a 5% CO2 humidified incu-
bator. Subsequently, 0.1 mM E. coli STa (Sigma) or double-
distilled acidified water (pH 2.3) (STa dilution buffer) was
added to each well, and incubations were continued for
15 min at 37C. The reaction was stopped by aspiration of
the incubation media and lysis of the cells by the addition
of 500 ml 5% ice-cold trichloracetic acid (TCA) for 30 min
at 4C. The resulting lysates were collected to glass tubes
and extracted twice with five volumes of ice-cold water-
saturated ether to remove TCA. Residual ether was removed
by evaporation in a chemical hood for additional 2 hr.
Samples were then frozen at 20C overnight and lyophi-
lized. After lyopilization, samples were resuspended in ace-
tic acid and acetylated with a mixture of acetic anhydride
and triethylamine to increase the sensitivity of the assay.
Cyclic GMP production wasmeasured with a commercially
available cGMP Enzyme Immunoassay kit (Biomedical
Technologies) according to the manufacturer’s specifica-
tions. All samples were analyzed in triplicate. Significant
activation of guanylate cyclase activity was seen in
HEK293 cells harboring the wild-type construct (HEK293:
GCC) in the presence of STa (Figure 3), comparable to that
seen in previously published studies.34 STa-mediated acti-
vation of guanylate cyclase in cells transfected with the
mutant construct (HEK293:GCCD387G) was ~60% lower
than that in cells harboring the wild-type construct
(Figure 3).
The association of GUCY2C with the MI phenotype
was further substantiated by our finding of a different
deleterious homozygous GUCY2C mutation in a severely
affected individual in another, unrelated kindred (Figure 1,012
family 2): a single case who had severe non-CF MI and was
born to Bedouin parents that were first cousins. The MI
phenotype in that individual was severe and required
surgery. The sweat test was normal, and homozygosity of
the affected individual at the CFTR locus was ruled out,
whereas homozygosity at the GUCY2C locus was demon-
strated (different haplotype than in family 1, data not
shown). Sequence analysis of GUCY2C identified a single
homozygous mutation, c.2270dupA (Figure 2D–F), not
found in 240 Bedouin nonrelated controls or in the
two healthy siblings of the affected individual. This
c.2270dupA insertion mutation results in a premature
stop codon two amino acids following the insertion
(p.Asn757Lysfs*2) and fully abrogates the guanylate cyclase
catalytic domain (Figure 2H). It should be noted that both
the c.1160A>G mutation and the c.2270dupA insertion
mutation were not reported to date in either the HapMap
or the 1000 genomes databases.
The fact that downregulation of GUCY2C leads to a
CF-like intestinal phenotype is in line with previous data
demonstrating that the secretory effect of guanylin is abol-
ished by CFTR blockers.50,51 Moreover, anti-CFTR anti-
bodies have been shown to prevent a cGMP-induced
increase in chloride secretion,52 and reduction of CFTR
expression in colonic carcinoma cells with antisense oligo-
nucleotides to CFTR mRNA diminished STa-induced chlo-
ride secretion. In fact, cells that do not express CFTR do not
respond to cGMP until transfected with CFTR cDNA.41
Further support for the interaction between GUCY2C
and CFTR comes from studies of mutant mice: mice lack-
ing functional CFTR have virtually no response to an
agonist elevating cGMP or cAMP concentrations,38 and
heterozygous CFTRþ/ mice demonstrate reduction of
STa secretory effect by about 50%.53 Because both cGMP
and cAMP secretory responses are impaired, CFTR null
mice, unlike GUCY2C null mice, suffer from severe
obstructions that result in high mortality.54 It should be
noted, though, that no complementation studies were
done with CFTR and GUCY2C mutant mice to prove their
interaction in vivo. Finally, in patients with CF treated
with STa and cGMP analogs, the failure to induce chloride
and water secretion results in resistance to STa-induced
diarrhea.55 Further in-vivo evidence for the connection
between GUCY2C and CFTR-associated effects comes
from studies of mice lacking functional PKGII, known to
mediate the GUCY2C effect on CFTR:56 in PKGII/
mice, the secretory response of the intestine to STa is mark-
edly reduced.57 As in GUCY2C-deficient mice, mice lack-
ing functional PKGII are otherwise healthy, indicating
that other transduction pathways, such as cAMP-protein
kinase A, might compensate for a cGMP-signaling deficit
in mice.
Although GUCY2C is highly expressed in the intestine,
its expression levels in the exocrine pancreas and in the
lungs are far lower,36,37 and CFTR activity in those other
CF-related tissues is dependent on other activators.1
Thus, affected individuals in this study do not demonstrateThe Amany features of the CF phenotype other than MI. Interest-
ingly, SNP rs9300298 at the 12p13.3 locus has been
associated with the MI phenotype in CF.22 However, this
SNP is located ~13 Mb from GUCY2C, and further detailed
association studies of this locus should be done to test
whether GUCY2C is a likely modifier of the MI phenotype
in CF.
Finally, we would like to note that mouse experiments
suggest a likely evolutionary advantage ofGUCY2C hetero-
zygous mutant individuals of the desert-dwelling Bedouin
community: in line with the partial penetrance of the
human phenotype we describe, null mutant mice lacking
functional GUCY2C protein have been generated and
are with no evident clinical phenotype when unchal-
lenged.31,42 However, although wild-type mice challenged
with the E. coli interotoxin STa die of severe secretory
diarrhea, Gucy2c/ null mutant mice are protected from
this detrimental effect. Moreover, even the heterozygous
mutant mice demonstrate lower diarrhea-related mortality
rates than the wild-type mice.31,42 As the human GUCY2C
mutations found are in Bedouin kindred whose habitat
is the desert, one can speculate that heterozygosity of
GUCY2C mutations might have led to selective advantage
at times of infectious diarrhea.Acknowledgments
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